Methodological issues of systematic reviews and meta-analyses in the field of sleep medicine: A meta-epidemiological study

Chang Xu a,*, Luis Furuya-Kanamori b, Joey S.W. Kwong c, Sheng Li d, Yu Liu e, Suhail A. Doi a

a Department of Population Medicine, College of Medicine, Qatar University, Doha, Qatar
b Research School of Population Health, Australian National University, Canberra, Australia
c JC School of Public Health and Primary Care, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong, China
d Department of Biological Repositories, Human Genetics Resource Preservation Center of Hubei Province, Zhongnan Hospital of Wuhan University, China
e Gansu Provincial Maternity and Child-care Hospital, Gansu, China

ARTICLE INFO

Article history:
Received 30 March 2020
Received in revised form 18 September 2020
Accepted 18 September 2020
Available online 24 January 2021

Keywords:
Evidence-based decision
Systematic reviews
Meta-analysis
Methodology validity
Meta-epidemiological study

SUMMARY

An increasing number of systematic reviews and meta-analyses (SRMAs) have been published in the field of sleep medicine. We evaluated the methodological issues of these SRMAs. A protocol was developed in advance. Three databases were searched from inception to October 2019 for SRMAs published in major academic journals of sleep medicine that assessed healthcare interventions. The AMSTAR 2.0 instrument was used to evaluate the methodological issues and a multivariable regression analysis was conducted to investigate potential measures associated with methodological validity. We identified 163 SRMAs. The median number of missing safeguards of these SRMAs was 7 out of 16 (Interquartile range, IQR: 6–9), and on average, two of these missing safeguards were critical weaknesses. Our regression analysis suggested that SRMAs published in recent years (β = 0.16; 95%CI: 0.08, 0.24; p = 0.002), with the first author from Europe (β = 0.08; 95%CI: 0.02, 0.14; p = 0.013) tend to have higher relative methodological ranks. In conclusion, the methodological validity for current SRMAs in sleep medicine was poor. Further efforts to improve the methodological validity are needed.

© 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Introduction

In the era of evidence-based medicine, credible evidence is the foundation upon which trustworthy decisions are built [1]. Systematic review and meta-analysis (SRMA) serves as an important source of evidence to support decision-making [2]. A systematic review summarizes findings from all available studies of the same topic, with or without a meta-analysis, and is expected to provide comprehensive evidence [3–5]. However, whether the evidence from a SRMA is credible largely rely on its design and conduct. These include but are not limited to 1) how the literature was searched and screened, 2) how the data were collected and analysed, and 3) how the results were interpreted and discussed. SRMAs involving methodological issues may generate non-credible results and mislead clinical practice [6].

In order to make a valid evaluation regarding methodological quality, several instruments have been developed in the past. These include the Sacks’ checklist [7], the Overview Quality Assessment Questionnaire [8], the Assessment of Multiple Systematic Reviews (AMSTAR) [9], and the updated version of AMSTAR (AMSTAR 2.0) [10]. These instruments are widely used to assess methodological issues related to SRMAs. Jadad et al. evaluated 50 SRMAs on the treatment of asthma and found that even after peer review there remain serious methodological flaws [11]. Xu et al. investigated 529 dose-response meta-analyses and found that 87.9% of them were poorly designed and conducted [12]. These studies reveal that a large proportion of SRMAs may have poorly implemented safeguards that validate their conclusions.

Since SRMA was introduced to the field of sleep medicine, there has been an increasing number of SRMAs published during the past decades, some of which have been used as evidence in clinical guidelines (e.g., [13–15]) that govern physician’s decisions, patients’ behaviours, and administrators’ policies. What makes things

Abbreviations: AMSTAR: Assessment of Multiple Systematic Reviews, AMSTAR 2.0; Systematic review and meta-analysis, SRMA; Interquartile range, IQR; Population, Intervention, Comparison, and Outcome, PICO.

* Corresponding author. Department of Population Medicine, College of Medicine, Qatar University, Al Jamaa Street, P. O. Box 2713, Doha, Qatar.
E-mail address: xuchang2016@runbox.com (C. Xu).

https://doi.org/10.1016/j.smrv.2021.101434
1087-0792/© 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
worrisome is the question around how well these SRMAs were designed and conducted and therefore whether the evidence they produced is credible. In this review, we conducted a comprehensive assessment to examine the methodological issues as well as investigate potential mechanisms to improve SRMAs conducted in the field of sleep medicine.

Methods

Protocol

A protocol for the meta-epidemiological study was developed in advance to formulate the design and conduct of this study (appendix 1). A meta-epidemiological study is defined as a methodological survey that “aims to evaluate trends and patterns in the literature with the overarching goal of improving the design, methods and conduct of future research” [16–18]. The protocol contained details regarding the review question, eligibility criteria, literature search, screen, quality assessment, data collection, and data analysis. Some changes were made: first, we limited the inclusion criteria to focus on systematic reviews with meta-analysis on healthcare interventions as suggested by the reviewers; second, we replaced the pre-defined subgroup analysis with a regression analysis considering that the interaction test of the potential difference of the effects among groups is underpowered when there are three or more categories [19]; further, we added a post-hoc sensitivity analysis for the regression to test the robustness of the results.

Eligibility criteria

We included systematic reviews with meta-analyses or meta-analyses alone on healthcare intervention published in the major academic journals of sleep medicine. We focused on healthcare intervention because AMSTAR 2.0 was designed to assess such types of systematic reviews [10]. Systematic reviews had to contain a quantitative synthesis, as the appropriate use of meta-analysis is part of the outcome of interest. The definition of systematic review has been clearly documented in the Cochrane handbook [20]. A meta-analysis refers to a statistical and quantitative synthesis of available findings of similar studies on the topic in question, which is generally regarded as a type of systematic review [21–24]. Overviews, scoping reviews, and narrative reviews were not considered since they differ from SRMAs [25]. Pooled analysis that do not use a regular literature search for at least one database were also not considered. Studies that consisted of original data plus a systematic review/overview/scoping review, again, were not considered. The primary outcome of the current review was the methodological flaws within the eligible studies. The secondary outcome was to examine the association between baseline characteristics (see data analysis part) and methodological weaknesses.

Literature search and screen

Literature search was conducted by one experienced researcher (XC). We searched for SRMAs published in academic journals in sleep medicine indexed in PubMed, Medline and Embase databases from inception to 22-Oct, 2019. We identified 23 related journals from Scimago Journal & Country Rank (https://www.scimagojr.com/) such as “Sleep”, “Sleep medicine reviews”, “Sleep medicine”. Of these we excluded four predatory journals (e.g., journal of sleep disorders & therapy) based on the Beall’s list and 19 journals were included. Of these non-predatory journals, we used indexing status as an additional criterion (MedLine versus non-MedLine). A full list of the journals and search strategy are presented in the appendix (appendix 1). Grey literature was not considered as we only aimed at peer reviewed SRMAs. We did not review the reference lists of eligible SRMAs since the sample would be sufficient and representative.

The Endnote X7 software was used to find duplicates. The Rayyan online app (https://rayyan.qcri.org/) was used for literature screening, which allows blinding of the raters to ensure the process was independent. Titles and abstracts were first screened by the lead author (XC) and those that were clearly not SRMAs were removed, a post hoc double-check of these excluded studies were performed by another author (LFK); the full-text of the remaining records were screened by two researchers (XC and LY) separately to make a further decision. Any disagreements were recorded and discussed until consensus was reached. The Cohen’s kappa statistics was used for assessing inter-rater agreement [26,27].

Data collection

Baseline characteristics such as first author’s name, number of authors, year of publication, region of affiliation of the first author, number of studies included, use of reporting guideline, funding information, type of main meta-analysis used in systematic reviews, and journal of publication of each SRMAs were extracted. This was done by one researcher (LY) and double checked by another researcher (XC). This information could be directly extracted and therefore no missing data was expected.

Meta-analyses were categorized as either a standard meta-analysis or a special type of meta-analysis. A standard meta-analysis was defined by use of classical synthesis methods based on head-to-head comparisons; special type of meta-analysis were those that involved more sophisticated assumptions and comparisons including diagnostic meta-analysis, dose–response meta-analysis, network meta-analysis, activation likelihood estimation meta-analysis, meta-analysis of prevalence, meta-analysis of means, meta-analysis of correlations, and meta-analysis of nucleotide polymorphism [28–40]. A detailed description of different types of meta-analyses is presented in Table S1.

Evaluation of methodological issues

The AMSTAR 2.0 instrument (https://amstar.ca/Amstar-2.php) was used to evaluate the potential methodological issues of eligible SRMAs [10]. The validity and reliability of this instrument has been critically assessed [41]. The AMSTAR 2.0 instrument (appendix 2) consists of 16 methodological items for SRMA; seven of which (items 2, 4, 7, 9, 11, 13, and 15) have been flagged as critical items [10]. In the current study, we did not consider item two as a critical item because the importance of protocol registration for methodological validity is not well verified [42]. Methodological weaknesses in any of the remaining six items would have greater impact on the validity of the SRMA and therefore the conclusions of the study.

The global methodology rating of a SRMA has routinely been judged by how many critical and non-critical weakness were identified, for example, high quality has been denoted as presence of none or only one non-critical weakness and critical low quality as two or more critical weakness [10]. However, such a judgement is somewhat arbitrary and anchors the assessment to the tool we have used. In order to make this universally valid, we used the relative quality rank as an alternative to measure the global methodological rating. This was done by enumerating items implemented out of 16 and creating a relative quality rank by dividing each enumerated count of safeguards by the maximum count across the SRMAs. The best SRMA thus has a rank of 1 (which serves as the anchor) and all lesser values are below this (range zero to 1).

There were two (“Yes” or “No”) possible responses for each item, except for items 2, 4, 7, 8, and nine where three possible responses
("Yes", "Partial Yes", "No") were available to rate the extent of a SRMA’s adherence to the criterion. If an item was rated as "No", it was regarded as a weakness for the SRMAs. If no information was provided, a “No” response was rated [10,43]. For item 8 (describes the characteristics of included studies adequately), there was no clear indicators to distinguish “Partial Yes” (described all components but not in details) and "Yes” (described all in details), thus we contacted the principle investigator of AMSTAR for clarification but did not receive a response. Therefore, we rated all eligible SRMAs that described required components of characteristics as “Partial Yes” for item eight to make a conservative evaluation. The enumerated counts considered “Yes” as one and “Partial Yes” as 0.5 while “No” was 0.

The lead author (XC), took charge of the assessment of methodological issues using the AMSTAR 2.0 tool. To ensure the quality of the process, at most 15 SRMAs were scheduled for assessment each day. A careful cross-checking process was utilised after the evaluation of all eligible SRMAs was completed. Then these records were double-checked by another researcher (LY). Any disagreements were discussed with two other methodologists (LFK and SD).

Data analysis

The baseline information of the SRMAs (e.g., author number, region) was qualitatively summarized. A bar chart was used to evaluate the of the process, at most 15 SRMAs were scheduled for assessment each day. A careful cross-checking process was utilised after the evaluation of all eligible SRMAs was completed. Then these records were double-checked by another researcher (LY). Any disagreements were discussed with two other methodologists (LFK and SD).

In order to investigate potential measures to improve the methodological validity, we established a weighted least squares regression for the relative quality rank against four predefined variables. The best SRMA thus has a rank of 1 (which serves as the anchor) and all lesser values are below this (range zero to 1). The predefined variables were: 1) region of affiliation of the first author (America, European, and Asia-Pacific), 2) year of publication ≤2009, 2010–2017, 2018-present), 3) number of authors (≤4, 5–7, ≥8), and 4) use of reporting guideline (Yes, No). We categorized year of publication based on the year of release of AMSTAR (2009) and AMSTAR 2.0 (2017) [9,10]. The number of authors were categorized by the quartiles. We did not use funding information as a dependent variable because it was already contained in the AMSTAR 2.0, which would break the i.i.d assumption of regression analysis [44]. Considering that SRMAs published in the same journal may have clustering on the methodological issues, a cluster robust-error variance was used in regression analysis [45].

A post hoc sensitivity analysis was employed under the consideration that the detection of publication bias (item 15) could be difficult or not defined for SRMAs with special types of meta-analyses (e.g., network meta-analysis) in the current period due to methodological constraints. Item 15 of AMSTAR 2.0 may not be well suited for these SRMAs. Therefore, we recomputed the relative quality ranks by removing SRMAs with special type meta-analysis and repeated the regression analysis to see if the results remained stable. The analyses were conducted using Stata 14.0/SE (StataCorp, College Station, TX) with confidence level set at 0.95.

Results

Baseline characteristics

The literature search identified 1630 records, of which 936 were identified as duplicates. We further excluded 104 records by screening the titles and abstracts (appendix 1). Of the remaining 590 records screened by full-text, 353 were SRMAs. Of which, we identified 163 that focused on healthcare interventions and were included in the analysis (Fig. 1). The kappa statistic was 0.66 between the two raters. A detailed description of the screening process, list of included studies, and list of excluded studies including the reasons for exclusion are available in appendix 1.

Baseline characteristics of the included studies are presented in Table 1 and appendix 3. For the 163 eligible SRMAs, most of which were published in 2010 and after (90.80%), only 9.20% were published before 2010. In terms of region of the first author, 38.65% (n = 63), 33.13% (n = 54), and 28.22% (n = 46) were from Asia—Pacific, America, and Europe, respectively. The median number of authors was 5 (interquartile range, IQR: 4 to 7); there were 37.42% SRMAs with 1–4 authors, 48.47% with 5–7 authors, and 14.11% with eight or more authors.

The majority of the meta-analyses within these SRMAs were standard meta-analyses (n = 157, 96.32%), and only 6 (3.68%) were special type meta-analyses. For SRMAs with special type meta-analyses, five were network meta-analysis and one was activation analysis. For the 12 with accessible protocol, 87 (53.37%) were supported by non-profit (government or institute) funding, 4 (2.45%) were supported by profit (industry) funding, 25 (15.34%) did not receive funding, and 47 (28.83%) did not report funding information.

Detailed methodological issues

The details of evaluation of the methodological issues for each SRMA are presented in appendix 3. Fig. 2 presents the adherence to each methodological item.

Issue 1. Research questions and inclusion criteria

Most of the SRMAs (n = 152, 93.25%; 95%CI: 88.32%, 96.19%) presented a clear research question and inclusion criteria in light of the population, intervention, comparison, and outcome (PICO). However, there were still some SRMAs that failed to clarify this (n = 11, 6.75%; 95%CI: 3.81%, 11.68%), of which seven failed to provide a clear comparison, four did not clearly specify the population and one did not specify both intervention and comparison.

Issue 2. Protocol registration

Protocol registrations were identified in 28 (17.18%; 95%CI: 12.16%, 23.71%) SRMAs. There were 10 SRMAs that reported a protocol was developed in advance, but failed to provide it, and we decided to rate these as “No”. For the 28 with accessible protocol, eight failed to develop a meta-analysis plan, a plan for investigating source of heterogeneity, and justify any changes from the protocol.

Issue 3. Study designs for inclusion

There were only 12 (7.36%; 95%CI: 4.26%, 12.42%) SRMAs that reported the reasons why certain study designs were included. Of which, one explained it in the abstract, and 11 explained it in the introduction or methods section. The majority (n = 151, 92.64%; 95% CI: 87.58%, 95.74%) of the SRMAs failed to report the reason. For the 12 SRMAs, three stated why only randomized controlled trials were included, seven reported why both randomized controlled trials and non-randomized studies of interventions were included, while the rest explained why only non-randomized studies were included.

Issue 4*. Literature search (Critical item)

In total, 19 (11.66%; 95%CI: 7.59%, 17.49%) of the SRMAs used a comprehensive literature search strategy that satisfies all the
components required (rated as “Yes”). In addition, 125 (76.69%; 95% CI: 69.63%, 82.52%) of the SRMAs searched two or more databases, provided keywords or strategy, and justified any limitations, which met the minimal requirement (rated as “Partial Yes”). However, there were 11.66% (95%CI: 7.59%, 17.49%; n = 19) of the SRMAs failed to use a comprehensive literature search (rated as “No”). The reasons were: 13 of them only searched one database and six did not provide keywords or search strategy.

**Issue 5. Duplicate study selection, literature screen**

There were 73.01% (95%CI: 65.72%, 79.24%; n = 119) of the SRMAs that stated that the study selection process was conducted by two reviewers independently (rated as “Yes”). It is notable that, of the 119 meta-analyses, only eight provided objective evidence (e.g., kappa statistic) that the process involved two reviewers.

**Issue 6. Duplicate data extraction**

Similarly, 63.19% (95%CI: 55.56%, 70.21%; n = 103) of the SRMAs stated that the data extraction process was conducted by two reviewers independently (rated as “Yes”). Again, only two of the 103 SRMAs provided objective evidence (kappa statistic) that the process involves two reviewers. More than one-third (n = 60, 36.81%; 95%CI: 29.79%, 44.44%) of the SRMAs failed to perform study selection in duplicate.

**Issue 7*. Study exclusion and justification (Critical item)**

Only 23 (14.11%; 95%CI: 9.59%, 20.28%) SRMAs provided a list of excluded studies and justify the reasons of exclusions, and 3 (1.84%; 95%CI: 0.63%, 5.27%) provided a list of excluded studies but without the reasons for exclusion. The remaining 137 (84.05%; 95%CI: 77.66%, 88.88%) failed to provide a full list of excluded studies, although two of them list a part of the excluded studies.

**Issue 8. Description of included studies**

In total, 139 (85.28%; 95%CI: 79.03%, 89.90%) SRMAs provided a clear description of population (P), intervention (I), comparator (C), outcome (O), and study design (S) of the included studies. However, there were 24 (14.72%; 95%CI: 10.1%, 20.97%) SRMAs that failed to
| Baseline characteristics                      | All publication (N = 163) |
|-----------------------------------------------|--------------------------|
| **Year**                                      |                          |
| ~2009                                        | 15 (9.20%)               |
| 2010–2017                                    | 88 (53.99%)              |
| 2018–present                                 | 60 (36.81%)              |
| **Region of first author**                   |                          |
| America                                      | 54 (33.13%)              |
| Asia–Pacific                                 | 63 (38.65%)              |
| European                                     | 46 (28.22%)              |
| **Author number [median (Q1, Q3)]**          |                          |
| < 5                                          | 61 (37.42%)              |
| 5–7                                          | 79 (48.47%)              |
| ≥8                                           | 23 (14.11%)              |
| **Type of meta-analysis**                    |                          |
| Generic meta-analysis                        | 157 (96.32%)             |
| Special type meta-analysis                   | 6 (3.68%)                |
| **Type of study included**                   |                          |
| RCTs                                         | 90 (55.21%)              |
| RCTs and NRSI                                | 47 (28.83%)              |
| NRSI                                         | 24 (14.72%)              |
| Not reported                                 | 2 (1.23%)                |
| **Use of reporting guidance**                |                          |
| Yes                                          | 79 (48.47%)              |
| No                                           | 84 (51.53%)              |
| **Protocol**                                 |                          |
| Yes, and accessible                          | 28 (17.18%)              |
| Yes, but not provided                        | 10 (6.13%)               |
| No                                           | 125 (76.69%)             |
| **Studies eligible for meta-analysis [median (Q1, Q3)]** |          |
| < 10                                         | 56 (34.36%)              |
| 10–29                                        | 76 (46.63%)              |
| ≥30                                          | 31 (19.02%)              |
| **Funding**                                  |                          |
| Non-profit funding                           | 87 (53.37%)              |
| Profit funding                               | 4 (2.45%)                |
| No funding                                   | 25 (15.34%)              |
| Not reported                                 | 47 (28.83%)              |

NRSI: non-randomized study of intervention (e.g., non-randomized controlled, pre-post study).

**Fig. 2.** Methodology adherence of eligible systematic reviews.
describe all of these components. In details, 13 out of 24 SRMAs failed to specify the study design of the included studies, four did not provide any description on PICOS, four did not describe the comparators, one did not describe the outcomes, and two did not describe at least two of the component (IC: 1, ICO: 1).

**Issue 9. Risk of bias assessment**

There were 89 (54.60%; 95%CI: 46.94%, 62.05%) SRMAs that adequately used a risk of bias assessment for all of the important biases. In addition, 35 (21.47%; 95%CI: 15.86%, 28.39%) of the SRMAs assessed part of the important biases (Randomized controlled trial: concealed allocation and blinding; Non-randomized studies of interventions: confounding and selection bias), which met the minimal requirement. The remaining 39 (23.03%; 95%CI: 18.03%, 31.03%) failed to achieve minimal requirements, of which, five did not report the assessment results, one did not report which tool was used, and 33 did not assess the risk of bias.

**Issue 10. Report on the sources of funding for included studies**

The majority of the SRMAs (n = 154, 94.48%; 95%CI: 89.84%, 97.97%) failed to report the funding information of included studies, and only 9 (5.52%; 95%CI: 2.93%, 10.16%) reported this item.

**Issue 11*. Methods for statistical combination**

For the statistical methods of combination, we identified 19 (11.66%; 7.57%, 17.49%) SRMAs with methodological issues to pool the data. The main problem was that most of them (n = 15) incorrectly combined different types of studies together (e.g., cohort and cross-sectional study), of which, three also had other problems, for example, did not consider confounding and heterogeneity. In addition, two did not report the method of how the data were synthesized; one used fixed-effect model and did not consider heterogeneity; and one did not report how adjustments for confounding were handled.

**Issue 12. Assess potential impact of risk of bias on the results**

Three methods out of those available [47] were used by the authors to incorporate risk of bias into the results in 20.86% (95%CI: 15.33%, 27.73%) of SRMAs. These included, stratification (n = 22), meta-regression (n = 3), and included only low risk bias studies (n = 9). However, the remaining majority of SRMAs (n = 129, 79.14%; 95%CI: 72.27%, 84.67%) failed to assess the potential impact of risk bias on the results.

**Issue 13*. Results interpretation with risk of bias**

Again, most of the SRMAs (n = 130, 79.75%; 95%CI: 72.60%, 85.47%) did not discuss risk of bias with the results interpretation notwithstanding if bias was incorporated into results or not. We documented 33 (20.25%; 95%CI: 14.80%, 27.07%) SRMAs did consider risk of bias in results interpretation of which 15 were those that had adjusted results for bias as reported above. Thus, most of these SRMAs failed to assess the potential impact of risk bias on the results.

**Issue 14. Exploring and explanation of heterogeneity**

There were 107 (65.64%; 95%CI: 58.06%, 72.50%) of the SRMAs that had a low between study heterogeneity or had some heterogeneity and attempted to explore the source of heterogeneity and discussed the potential impact on the conclusions. There were 56 SRMAs (34.36%; 95%CI: 27.50%, 41.94%) had some heterogeneity but did not explore the source.

**Issue 15*. Investigation and discussion of publication bias**

There were 76 (46.63%; 95%CI: 39.14%, 54.28%) SRMAs that investigated publication bias and discussed the potential influence on the results (rated as "Yes"). In addition, 23 (14.11%; 95%CI: 9.59%, 20.28%) investigated publication bias but failed to discuss the potential influence (rated as "Partial Yes"). As much as 64 (39.26%; 95%CI: 32.09%, 46.92%) did not include investigation of publication bias (rated as "No"). Amongst the 64, 58 did not detect publication bias, and six did not provide results of publication bias. The reasons were recorded by nine SRMAs that the number of included studies were too small to assess publication bias.

**Issue 16. Report sources of conflict of interest**

Source of conflict of interest was reported by the majority of the SRMAs (n = 158, 96.93%; 95%CI: 93.02%, 98.68%).

**Rating of each issue and global confidence**

Fig. 3 presents the ranking for each item in light of the proportion of number of "No". The majority of the SRMAs have a poor validity on protocol registration (item 2), study designs for inclusion (item 3), study exclusion and justification (item 7), report on the sources of funding for included studies (item 10), assess potential impact of risk of bias on the results (item 12), results interpretation with risk of bias (item 13); Of these, two of them (item 7 and 13) were critical important domains. In addition, about one-fourth to two-fifth of the SRMAs have a poor validity on study selection (item 5), data extraction (item 6), risk of bias assessment (item 9), heterogeneity exploring and explanation (item 14), and investigation and discussion of publication bias (item 15); again, two of them (item nine and 15) were critical important domains. For the remaining five methodological items (item 1, 4, 8, 11, and 16), the validity was well-quantified by most of the SRMAs.

Fig. 4 presents the distribution of number of total weakness and critical weakness for these SRMAs. The median number of total and critical weakness were 7 (Inter Quartile Range, IQR: 6–9) and 2 (IQR: 2–3).

For total items, the best SRMA had a safeguard count of 12.5 and thus was regarded as the anchor for relative ranks. The median relative rank was 0.64, with the first quartile as 0.52 and the third quartile as 0.72 (Fig. 4). This indicated that the top quartile SRMAs had up to a third (0–28%) of methodological safeguards missing. For six critical items, the best SRMA had a count of six meaning that all the six critical items were well adhered to. The median relative rank was 0.5, with the first quartile as 0.33 and the third quartile as 0.58 (Fig. 4). This indicated that the top quartile SRMAs had up to almost half (0–42%) methodological safeguards missing.

**Regression analysis**

Our regression analysis suggested that, for total relative ranks, studies with first author from the Europe (estimated $\beta = 0.08; 95\% CI: 0.02, 0.14; p = 0.013$), published more recently (e.g., 2010 to 2017 vs. 2009 and before, estimated $\beta = 0.16; 95\% CI: 0.08, 0.24; p = 0.002$), and involves more authors ($\geq 8$ vs. $< 4$; estimated $\beta = 0.06; 95\% CI: 0.01, 0.11; p = 0.026$) were associated with higher relative quality ranks. These associations were similar for critical items: estimated $\beta$ were 0.09 (95% CI: 0.03, 0.14; p = 0.007) for studies with first author from the Europe, 0.14 (95% CI: 0.005, 0.27; p = 0.043) for studies published between 2010 and 2017. While the association were no longer observed for studies with eight or more authors (estimated $\beta = 0.01; 95\% CI: −0.08, 0.09; p = 0.865$), Table 2. Sensitivity analysis, after the exclusion six SRMAs with special type meta-analysis, suggested the associations were mostly stable (Table 2), except for the publication data (estimated $\beta = 0.14; 95\% CI: −0.004, 0.28; p = 0.056$).

C. Xu, L. Furuya-Kanamori, J.S.W. Kwong et al. Sleep Medicine Reviews 57 (2021) 101434
Fig. 3. Rating for the proportion of weakness of each item.

Fig. 4. Histogram for the distribution of the number of total and critical weakness as well as the relative ranks of the methodological quality (Y-axis is the frequency).
We found that use of a reporting guideline did not help to increase the methodological validity of SRMAs for both global quality and critical items. This could be expected because reporting guidelines were primarily designed to help authors remember all items that need to be reported, rather than to conduct a SRMA [48]. However, some of the methodological issues were highly correlated with reporting problems, for example description of the inclusion criteria, study section, baseline characteristic, and conflict of interests. The role of reporting guideline on the methodological validity should be further investigated through well-designed experimental studies.

The findings of the current study concurred with reviews from other fields (e.g., urology, bariatrics, general surgery) [49–54]. For example, Corbyons et al. conducted a survey on SRMAs published in urology and their findings suggested that the methodological quality of these studies was suboptimal [49]; Storman et al. found that 99% of the published systematic reviews/meta-analyses in bariatric surgery were critically low on methodological quality [50]. These findings revealed that, many SRMAs may have serious methodological issues.

In this review, we did not use the rating scheme recommended by AMSTAR 2.0 to rate the methodology confidence of eligible, instead, the relative rank method was utilized. In addition to the reason we mentioned earlier (i.e., subjective judgment), the rating scheme of this instrument is not sensitive to distinguish the confidence of SRMAs with critical low quality – all SRMAs with two or more critical issues were rated as critical low. Indeed, a SRMAs with two critical issues might be more credible than one with three critical issues. The relative rank method provides a better solution to rate the confidence and can avoid such problems.

We did not consider protocol registration as a critical item. Our previous study suggested that developing a protocol in advance although of benefit to improve reporting, may not represent the methodological quality of SRMAs well [55]. Waugh [42] has pointed out six issues with such registration 1) confidentiality of research ideas, 2) deference of others from similar research that may be of higher quality, 3) no clear relevance of information requested in PROSPERO, 4) no clear benefit in terms of precedence in registration, 5) no clear mandate from the academic community, and 5) finally the cost of time spent versus effectiveness of the process. This whole concept needs revisiting to assess its fitness for purpose.

Based on current findings and our experiences, we proposed some recommendations about dos and don’ts of SRMAs beyond the AMSTAR 2.0 instrument: 1) when starting a SRMA, it is

### Table 2
Regression analysis of relative quality ranks of the methodology to four pre-defined variables.

| Variables                      | Systematic reviews with standard meta-analysis | Total items | Critical items | Total items | Critical items |
|-------------------------------|-----------------------------------------------|-------------|----------------|-------------|----------------|
| **Region**                    |                                               |             |                |             |                |
| America                       | Reference                                     | 0.06 (0.01, 0.13) | 0.075 | 0.09 (0.03, 0.14) | 0.007 |
| Asia–pacific                  | Reference                                     | 0.09 (0.03, 0.14) | 0.013 | 0.12 (0.07, 0.18) | 0.001 |
| European                      | Reference                                     | 0.08 (0.02, 0.14) | 0.104 | 0.12 (0.07, 0.18) | 0.001 |
| **Year of publication**       |                                               |             |                |             |                |
| 2009 and before               | Reference                                     | 0.06 (0.02, 0.07) | 0.217 | 0.00 (0.05, 0.05) | 0.980 |
| 2010 to 2017                  | Reference                                     | 0.014 (0.005, 0.27) | 0.004 | 0.08 (0.07, 0.23) | 0.245 |
| 2018 to present               | Reference                                     | 0.004 (0.005, 0.27) | 0.007 | 0.09 (0.03, 0.14) | 0.007 |
| **Number of authors**         |                                               |             |                |             |                |
| ≤4                            | Reference                                     | 0.06 (0.01, 0.11) | 0.026 | 0.01 (0.08, 0.09) | 0.865 |
| 5 to 7                        | Reference                                     | 0.00 (0.05, 0.10) | 0.004 | 0.08 (0.07, 0.23) | 0.245 |
| ≥8                            | Reference                                     | 0.06 (0.01, 0.11) | 0.026 | 0.01 (0.08, 0.09) | 0.865 |
| **Use of reporting guidance** |                                               |             |                |             |                |
| No                            | Reference                                     | 0.05 (0.005, 0.10) | 0.071 | 0.04 (0.03, 0.11) | 0.246 |
| Yes                           | Reference                                     | 0.06 (0.01, 0.12) | 0.08 | 0.04 (0.03, 0.11) | 0.225 |

### Table 3
Sensitivity analysis of systematic reviews with meta-analysis after excluding six special type meta-analyses.

| Variables                      | Primary analysis | Sensitivity analysis |
|-------------------------------|-----------------|---------------------|
| **Region**                    | Total items | P | Critical items | P |
| America                       | Reference | Reference | 0.06 (0.01, 0.13) | 0.075 | 0.09 (0.03, 0.14) | 0.007 |
| Asia–pacific                  | Reference | Reference | 0.09 (0.03, 0.14) | 0.013 | 0.12 (0.07, 0.18) | 0.001 |
| European                      | Reference | Reference | 0.08 (0.02, 0.14) | 0.104 | 0.12 (0.07, 0.18) | 0.001 |
| **Year of publication**       | Total items | P | Critical items | P |
| 2009 and before               | Reference | Reference | 0.06 (0.02, 0.07) | 0.217 | 0.00 (0.05, 0.05) | 0.980 |
| 2010 to 2017                  | Reference | Reference | 0.014 (0.005, 0.27) | 0.004 | 0.08 (0.07, 0.23) | 0.245 |
| 2018 to present               | Reference | Reference | 0.004 (0.005, 0.27) | 0.007 | 0.09 (0.03, 0.14) | 0.007 |
| **Number of authors**         | Total items | P | Critical items | P |
| ≤4                            | Reference | Reference | 0.06 (0.01, 0.11) | 0.026 | 0.01 (0.08, 0.09) | 0.865 |
| 5 to 7                        | Reference | Reference | 0.00 (0.05, 0.10) | 0.004 | 0.08 (0.07, 0.23) | 0.245 |
| ≥8                            | Reference | Reference | 0.06 (0.01, 0.11) | 0.026 | 0.01 (0.08, 0.09) | 0.865 |
| **Use of reporting guidance** | Total items | P | Critical items | P |
| No                            | Reference | Reference | 0.05 (0.005, 0.10) | 0.071 | 0.04 (0.03, 0.11) | 0.246 |
| Yes                           | Reference | Reference | 0.06 (0.01, 0.12) | 0.08 | 0.04 (0.03, 0.11) | 0.225 |
helpful to design and conduct it according to a well-designed instrument (e.g., AMSTAR 2.0 [10]); 2) when including both observational and experimental studies in a SRMA, it is not recommended to incorporate data of these two types of studies together as the former would introduce risk of reverse causality; 3) it is highly recommended to explain the selection of effect estimator (e.g., odds ratio, risk ratio) to measure the effects in the meta-analysis and how the effect estimators were dealt with when difference estimators were used by these studies; 4) it is recommended to use two or more weighting methods as sensitivity analysis when the effect was small but statistically significant; 5) if applicable, a dose–response gradient should be investigated; 6) when measuring publication bias, P-value driven methods (e.g., Egger’s test, rank correlation test [56]) are discouraged as these are dependent on the number of studies included in a meta-analysis, instead non-P-value driven methods (e.g., LFK index [57]) should be used.

In this review, we employed a comprehensive evaluation of SRMAs in sleep medicine, to the best of our knowledge, this is the first study that focuses on the methodological issues of SRMAs in this field. We collected nearly all published SRMAs of healthcare intervention in the field of sleep medicine, therefore, our findings have a high level of representativeness. We acknowledge that our review had some limitations. In this study, the literature search was based on 19 academic journals of sleep medicine that there was no doubt that some related studies published in other journals (e.g., general journals) were not included, which may bring some selection bias on the results. Previous study had document that the methodology quality of meta-analysis may differs from general journals and specialist journals [58]. However, it is difficult to identify meta-analyses on this topic (sleep) from other journals. Further, our study put focus on the methodological validity of SRMAs, while neglected the importance of the quality of individual studies included in these SRMAs. The quality of these original studies is also very important. In addition, as we mentioned earlier, some methodology tips may not well reflected and covered in the AMSTAR 2.0, which may affect the validity of current survey. Moreover, the screen and assessment processes, although were strict, may still at risk of systematic errors since both were of somewhat subjective. These limitations should be highlighted and merit attention in the results interpretation.

Conclusions

In conclusion, the methodological validity of SRMAs of healthcare intervention was suboptimal when measured by AMSTAR 2.0 in the field of sleep medicine. Although the it has improved over time, methodological confidence was lacking for most of these SRMAs. Based on current findings, we advocate a critical evaluation on the methodological validity of a SRMA before it can be used as clinical evidence.

**Research agenda**

**Future studies should:**

1. Undertake a critical evaluation of the methodological validity of a systematic review before using it as clinical evidence.
2. More focus should be put on the methodological validity of the systematic reviews and meta-analyses rather than simple checklists followed by inexperienced researchers.
3. Rigorous guidelines for the methodology for different types of meta-analysis are needed to help systematic reviews’ authors to improve the methodological quality of what they create.

**Authors’ contributions**

XC conceived and designed the study, conducted the literature search, analyzed the data, plotted the figures and tables, and drafted the manuscript; XC and LY contributed to the quality assessment and data collection; LFK and SD provided statistical guidance and edited the draft; LFK, SD, JK, LS provided further comments for the manuscript. All authors approved the final version.

**Funding**

L FK was supported by Australian National Health and Medical Research Council Early Career Fellowships (APP1158469).

**Conflicts of interest**

None.

**Acknowledgments**

Open Access funding provided by the Qatar National Library.

**Appendix A. Supplementary data**

Supplementary data to this article can be found online at https://doi.org/10.1016/j.smrv.2021.101434.

**References**

[1] Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schünemann HJ. What is “quality of evidence” and why is it important to clinicians? BMJ 2008;336(7651):995–8.
[2] Gurevitch J, Koricheva J, Nakagawa S, Stewart G. Meta-analysis and the science of research synthesis. Nature 2018;555(7695):175–82.
[3] Cook DJ, Mulrow CD, Haynes RB. Systematic reviews: synthesis of best evidence for clinical decisions. Ann Intern Med 1997;126(5):376–80.
[4] Murad MH, Montori VM, Ioannidis JP, Jaeschke R, DeVereaux PJ, Prasad K, et al. How to read a systematic review and meta-analysis and apply the results to patient care: users’ guides to the medical literature. J Am Med Assoc 2014;312(2):171–9.
[5] Noordzij M, Hooft L, Dekker FW, Zoell C, Jager KJ. Systematic reviews and meta-analyses: when they are useful and when to be careful. Kidney Int 2009;76(11):1130–6.
[6] Stone J, Gurunathan U, Glass K, Munn Z, Tugwell P, Doi SAR. Stratification by quality induced selection bias in a meta-analysis of clinical trials. J Clin Epidemiol 2019;107:51–9.

* The most important references are denoted by an asterisk.
